Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|October 2, 2001
- Pharmaceutical Technology-10-02-2001
- Volume 25
- Issue 10
Near-Infrared Inspection Complements Other QC Systems
Author(s)Hallie Forcinio
NIR quality control technology, relatively new to the pharmaceutical industry, could revolutionize processing and packaging.
Advertisement
Articles in this issue
about 25 years ago
Outsourcing Outlookabout 25 years ago
Hydrogels for the Controlled Release of Pharmaceutical Proteinsabout 25 years ago
Safety and Manufacturing Standardsabout 25 years ago
Current Status of the Oral Delivery of Insulinabout 25 years ago
Laboratory Equipment Qualificationabout 25 years ago
Filter Integrity Testing in Liquid Applications, Revisited, Part IAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement